Cancer chemotherapy in the elderly.
As the geriatric population is growing, it is increasingly important to be familiar with chemotherapy for the elderly. Age-related changes in pharmacokinetics are documented for doxorubicin, etoposide, ifosfamide, daunorubicin, mitomycin, cisplatin and methotrexate. The hematological toxicity of most standard-dose chemotherapy is not affected by age in patients with normal organic functions and good performance status, although increased toxicity with aging is suggested in the use of actinomycin-D, etoposide, vinblastin, methotrexate, methyl-CCNU, doxorubicin and mitomycin, and in dose-intensive chemotherapy. Among non-hematological toxicities, only doxorubicin-induced cardiomyopathy and bleomycin-induced pulmonary toxicity are demonstrated to be accelerated in the elderly. There is no evidence that advanced age decreases the efficacy of chemotherapy for tumors, except for Hodgkin's disease and acute leukemia. These results suggest that advanced chronological age alone is not always associated with severe toxicity and poor prognosis, and that many elderly patients with cancer will benefit from chemotherapy. To answer questions regarding the optimal chemotherapy regimen, dose and intensity in this population, the influence of age should be analyzed in a multivariate approach in future studies.
Sekine
I
I
Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan. isekine@gan2.ncc.go.jp
Fukuda
H
H
Kunitoh
H
H
Saijo
N
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D000880:Anthraquinones / Q000493:pharmacokinetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D002066:Busulfan / Q000493:pharmacokinetics / Q000627:therapeutic use; D003630:Daunorubicin / Q000493:pharmacokinetics / Q000627:therapeutic use; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000627:therapeutic use; D005047:Etoposide / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000493:pharmacokinetics / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008168:Lung / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011720:Pyrazoles / Q000493:pharmacokinetics / Q000627:therapeutic use
D000880:Anthraquinones; D000970:Antineoplastic Agents; D011720:Pyrazoles; D005047:Etoposide; D004317:Doxorubicin; D002066:Busulfan; D005472:Fluorouracil; C046659:piroxantrone; D003630:Daunorubicin